Xolair significantly improves itch in patients with severe form of chronic skin disease CSU, Novarti

Xolar (omalizumab) was showed to be effective, safe and well tolerated in refractory refractory chronic spontaneous urticarial (CSU) patients, including those on antihistamines at up to four times the approved dose, Novartis Korea said on Tuesday.

Last month, Novartis announced its late-breaking results showing omalizumab met all primary and secondary endpoints of a pivotal Phase III safety ...